KDM6B and head and neck squamous cell carcinoma: Of course, given the targeting specificity of GSK-J1 and TCP,51 we here cannot rule out the possibility that other mediators beyond LSD1 and JMJD3 might also account for therapeutic effects of TCP and GSK-J1 in HNSCC.